In case you missed it – we have recently joined forces with Oxitope Pharma to form Calluna Pharma, a clinical stage company developing novel therapies that harness the transformative potential of the body's immune system. Make sure your follow Calluna for the latest updates! 👇
Big news! Unveiling Calluna Pharma – a clinical stage company pioneering a breakthrough approach to treating inflammatory and fibrotic diseases by leveraging the body’s innate immune system. Calluna Pharma is the result of the successful merger between Arxx Therapeutics and Oxitope Pharma, backed by existing investors Forbion, Sarsia, p53, and Investinor. Together, we are forging a path towards groundbreaking advancements in harnessing the innate immune system to revolutionize disease modulating therapies. Our combined expertise in the realm of innate immunity, positions Calluna as a leader in the field. Our robust pipeline of selective antibodies targeting innate immune amplifiers of disease, enables us to fulfil unmet medical needs across a spectrum of chronic and acute diseases. Join us on this exciting journey as we develop novel therapies with the aim of reshaping the landscape of immunological diseases. Stay tuned for updates as we continue to grow and drive progress in the field. Want to learn more in the meantime? Visit our website here: https://lnkd.in/e37y2VKy #PressRelease #Biologics #DrugDevelopment #Clinical #PrecisionMedicine